FDA Approves Tirzepatide, A Potential Blockbuster Drug for Type 2 Diabetes | Biopharma PEG
FDA Approves Drug Tirzepatide for Type 2 Diabetes
Developments in diabetes management: What do we know about tirzepatide? - Hospital News
Diabetes Distilled: The twincretin tirzepatide – a promising treatment for NAFLD - DiabetesontheNet
Type 2 Diabetes Treatment to Lower A1C | Mounjaro® (tirzepatide)
Tirzepatide's Unique Mechanism of Action - GIP/GLP-1 Dual Agonist - YouTube
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology | Full Text
Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA
PDF) Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Adults with type 2 diabetes reach HbA1c target faster with tirzepatide than semaglutide
Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes
Frontiers | Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist - ScienceDirect
Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes – touchENDOCRINOLOGY
Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions | ADA
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - The Lancet
Efficacy and safety of three dose-escalation algorithms of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes - Media Centre | EASD
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial - The Lancet
A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes - Furihata - 2022 - Diabetes, Obesity and Metabolism - Wiley Online Library
Tirzepatide for diabetes: on track to SURPASS current therapy | Nature Medicine
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial - The
Tirzepatide (Mounjaro): A Q&A With the ADA's Dr. Robert Gabbay | Everyday Health
Frontiers | Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
New Drug Tirzepatide Shows Extraordinary Results For Obesity and Type 2 Diabetes
